Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ITOC 2015 /
PD-1 inhibition in lung cancer: Paving the way for a brighter future

25th - 27th Mar 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.05.15
Views: 2648

Prof Peter Brossart - University Hospital Bonn, Bonn, Germany

Prof Brossart talks about the increase in new cases of lung cancer and the disease’s mortality rate, as well as the use of targeted therapies and inhibitors in EGFR mutation-positive NSCLC.

Also, the treatment options for patients with advanced NSCLC and how they differ according to histology.

See also:

Raising the bar in melanoma treatment with immuno-oncology

Immuno-oncology: Changing the landscape of cancer therapy

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation